Fisher J, Mangla A, Mack RJ, Borer JS. Calcium antagonists and nitrates in pulmonary hypertension: recent findings. Drug Therapy December, 1984.

Mangla A, Fisher J, Libby DM, Saddekni S. Sarcoidosis, pulmonary hypertension and acquired peripheral pulmonary stenosis. Catheterization and Cardiovascular Diagnosis 1985; 11: 69-74.

Chin RG, Fisher J. Hypothyroidism and pulmonary hypertension: observation and speculation. Cardiovasc Rev Report 1986; 7: 789-796.

Fisher J, Mack RJ, Likier HM, Schiff AN, Borer JS. Nifedipine in pulmonary arterial hypertension: importance of Raynaud’s phenomenon. Chest 1987; 92: 400-405.

Fisher J, Borer JS, Moses JW, Goldberg HL, Niarchos AP, Whitman HH, Mermelstein M. Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. Amer J Cardiol 1984; 54:646-650.

Fisher J, Mangla A, Mack RJ, Borer JS. Calcium antagonists and nitrates in pulmonary hypertension: recent findings. Drug Therapy December, 1984.

Fisher J, Borer JS. Nifedipine and hydralazine for primary pulmonary hypertension. Cardiology Bd Review 1985; 2: 67-75.

Fisher J, Mack RJ, Likier HM, Schiff AN. Recognition and management of the patient with pulmonary hypertension. Cardiovasc Rev Report 1985; 6: 1331-1334.

Fisher J, Borer JS, Moses JW, Goldberg HL, Mack RJ, Niarchos AP, Whitman HH, Mermelstein M. Comparative effects of nifedipine and hydralazine in pulmonary arterial hypertension. Cardiovasc Rep Report 1986; 3: 251-256.

Fisher J, Mack RJ, Liker HM, Schiff AN, Borer JS. Nifedipine in pulmonary arterial hypertension: importance of Raynaud’s phenomenon. Chest 1987; 92:400-405.

Groves BM, Kernis J, Brundage BH, Dantzker DR, Elliott CG, Fishman AP, Koerner SK, Moser KM, Fisher JD, Pietro AP, Peter RH, Reeves JT, Rich S, Round S. Pulmonary Hypertension Associated with Cirrhosis Compared with Primary (unexplained) Pulmonary Hypertension. In: Pulmonary Circulation, Normal and Abnormal, Fishman AP, (ed) Univ. Penn. Press, 1990, 359-369.